Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham Purchases 50,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) Director G. Walmsley Graham purchased 50,000 shares of Akero Therapeutics stock in a transaction dated Thursday, March 27th. The shares were purchased at an average price of $43.55 per share, for a total transaction of $2,177,500.00. Following the completion of the acquisition, the director now owns 1,200,000 shares of the company's stock, valued at approximately $52,260,000. The trade was a 4.35 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

G. Walmsley Graham also recently made the following trade(s):

• On Tuesday, March 25th, G. Walmsley Graham bought 91,309 shares of Akero Therapeutics stock. The shares were acquired at an average cost of $44.75 per share, for a total transaction of $4,086,077.75.
• On Thursday, January 30th, G. Walmsley Graham acquired 200,000 shares of Akero Therapeutics stock. The stock was acquired at an average cost of $48.00 per share, for a total transaction of $9,600,000.00.

Akero Therapeutics Stock Down 7.3 %

AKRO stock traded down $3.10 during midday trading on Monday, reaching $39.62. 414,793 shares of the company's stock traded hands, compared to its average volume of 817,582. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm's fifty day moving average price is $46.01 and its 200-day moving average price is $35.15. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40. The company has a market cap of $3.15 billion, a price-to-earnings ratio of -10.58 and a beta of -0.19.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its position in shares of Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company's stock worth $226,554,000 after buying an additional 2,782,029 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Akero Therapeutics during the 3rd quarter valued at about $37,392,000. RTW Investments LP increased its holdings in Akero Therapeutics by 15.9% during the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after acquiring an additional 940,388 shares during the period. Deep Track Capital LP raised its position in shares of Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after buying an additional 800,216 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Akero Therapeutics in the 4th quarter valued at about $18,059,000.

Analyst Ratings Changes

AKRO has been the topic of a number of recent analyst reports. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. HC Wainwright upped their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup boosted their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Finally, UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Akero Therapeutics currently has an average rating of "Buy" and an average target price of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.